As of May 26
| -0.25 / -1.67%|
The 8 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 26.00 and a low estimate of 6.00. The median estimate represents a +8.47% increase from the last price of 14.75.
The current consensus among 8 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since May, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.